Ligand-based design of GLUT inhibitors as potential antitumor agents

Suliman Almahmoud; Wei Jin; Liying Geng; Jing Wang; Xiaofang Wang; Jonathan L. Vennerstrom; Haizhen A. Zhong

doi:10.1016/j.bmc.2020.115395

Ligand-based design of GLUT inhibitors as potential antitumor agents

Suliman Almahmoud, Wei Jin, Liying Geng, Jing Wang, Xiaofang Wang, Jonathan L. Vennerstrom, Haizhen A. Zhong

Research output: Contribution to journal › Article

1 Scopus citations

Abstract

Glucose transporters (GLUTs) regulate glucose uptake and are often overexpressed in several human tumors. To identify new chemotypes targeting GLUT1, we built a pharmacophore model and searched against a NCI compound database. Sixteen hit molecules with good docking scores were screened for GLUT1 inhibition and antiproliferative activities. From these, we identified that compounds 2, 5, 6 and 13 inhibited the cell viability in a dose-dependent manner and that the IC₅₀s of 2 and 6 are<10 µM concentration in the HCT116 colon cancer cell line. Lead compound 13 (NSC295720) was a GLUT1 inhibitor. Docking studies show that GLUT1 residues Phe291, Phe379, Glu380, Trp388, and Trp412 were important for inhibitor binding.

Original language	English (US)
Article number	115395
Journal	Bioorganic and Medicinal Chemistry
Volume	28
Issue number	7
DOIs	https://doi.org/10.1016/j.bmc.2020.115395
State	Published - Apr 1 2020

Keywords

Anticancer
Docking
GLUT1
Glucose
Pharmacophore

ASJC Scopus subject areas

Biochemistry
Molecular Medicine
Molecular Biology
Pharmaceutical Science
Drug Discovery
Clinical Biochemistry
Organic Chemistry

Access to Document

10.1016/j.bmc.2020.115395

Fingerprint Dive into the research topics of 'Ligand-based design of GLUT inhibitors as potential antitumor agents'. Together they form a unique fingerprint.

Cite this

Almahmoud, S., Jin, W., Geng, L., Wang, J., Wang, X., Vennerstrom, J. L., & Zhong, H. A. (2020). Ligand-based design of GLUT inhibitors as potential antitumor agents. Bioorganic and Medicinal Chemistry, 28(7), [115395]. https://doi.org/10.1016/j.bmc.2020.115395

@article{c9da5719fe7840fd8bb96be10f1d8d0a,

title = "Ligand-based design of GLUT inhibitors as potential antitumor agents",

abstract = "Glucose transporters (GLUTs) regulate glucose uptake and are often overexpressed in several human tumors. To identify new chemotypes targeting GLUT1, we built a pharmacophore model and searched against a NCI compound database. Sixteen hit molecules with good docking scores were screened for GLUT1 inhibition and antiproliferative activities. From these, we identified that compounds 2, 5, 6 and 13 inhibited the cell viability in a dose-dependent manner and that the IC50s of 2 and 6 are<10 µM concentration in the HCT116 colon cancer cell line. Lead compound 13 (NSC295720) was a GLUT1 inhibitor. Docking studies show that GLUT1 residues Phe291, Phe379, Glu380, Trp388, and Trp412 were important for inhibitor binding.",

keywords = "Anticancer, Docking, GLUT1, Glucose, Pharmacophore",

author = "Suliman Almahmoud and Wei Jin and Liying Geng and Jing Wang and Xiaofang Wang and Vennerstrom, {Jonathan L.} and Zhong, {Haizhen A.}",

year = "2020",

month = apr,

day = "1",

doi = "10.1016/j.bmc.2020.115395",

language = "English (US)",

volume = "28",

journal = "Bioorganic and Medicinal Chemistry",

issn = "0968-0896",

publisher = "Elsevier Limited",

number = "7",

}

TY - JOUR

T1 - Ligand-based design of GLUT inhibitors as potential antitumor agents

AU - Almahmoud, Suliman

AU - Jin, Wei

AU - Geng, Liying

AU - Wang, Jing

AU - Wang, Xiaofang

AU - Vennerstrom, Jonathan L.

AU - Zhong, Haizhen A.

PY - 2020/4/1

Y1 - 2020/4/1

N2 - Glucose transporters (GLUTs) regulate glucose uptake and are often overexpressed in several human tumors. To identify new chemotypes targeting GLUT1, we built a pharmacophore model and searched against a NCI compound database. Sixteen hit molecules with good docking scores were screened for GLUT1 inhibition and antiproliferative activities. From these, we identified that compounds 2, 5, 6 and 13 inhibited the cell viability in a dose-dependent manner and that the IC50s of 2 and 6 are<10 µM concentration in the HCT116 colon cancer cell line. Lead compound 13 (NSC295720) was a GLUT1 inhibitor. Docking studies show that GLUT1 residues Phe291, Phe379, Glu380, Trp388, and Trp412 were important for inhibitor binding.

AB - Glucose transporters (GLUTs) regulate glucose uptake and are often overexpressed in several human tumors. To identify new chemotypes targeting GLUT1, we built a pharmacophore model and searched against a NCI compound database. Sixteen hit molecules with good docking scores were screened for GLUT1 inhibition and antiproliferative activities. From these, we identified that compounds 2, 5, 6 and 13 inhibited the cell viability in a dose-dependent manner and that the IC50s of 2 and 6 are<10 µM concentration in the HCT116 colon cancer cell line. Lead compound 13 (NSC295720) was a GLUT1 inhibitor. Docking studies show that GLUT1 residues Phe291, Phe379, Glu380, Trp388, and Trp412 were important for inhibitor binding.

KW - Anticancer

KW - Docking

KW - GLUT1

KW - Glucose

KW - Pharmacophore

UR - http://www.scopus.com/inward/record.url?scp=85080096887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85080096887&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2020.115395

DO - 10.1016/j.bmc.2020.115395

M3 - Article

C2 - 32113844

AN - SCOPUS:85080096887

VL - 28

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 7

M1 - 115395

ER -